The FDA will want long-term cardiovascular outcome context
Vendor Evaluation Methodology When comparing tesamorelin/ipamorelin blend vendors: Price Competitiveness (40%) Normalize to cost per total milligram
The MDS-UPDRS and CDR-SB cannot cleanly separate symptomatic relief from disease modification, and EVOKE showed the converse failure mode, biomarker movement without clinical benefit, so future trials should anchor on objective measures such as dopamine-transporter SPECT, neurofilament light chain, and tau, amyloid, and neuroinflammation PET
Some witnessed their blood sugar go way down
Since this is a multi-dose vial with a preservative, it can be used for multiple doses in the same patient
Your healthcare provider can help adjust your treatment plan or provide additional solutions tailored to your needs